世界の拡張型心筋症治療市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV11673)
◆英語タイトル:Global Dilated Cardiomyopathy Treatment Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV11673
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:95
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは拡張型心筋症治療の世界市場について調査・分析した資料です。種類別(薬物、植込み型除細動器)の市場規模、用途別(病院・クリニック、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別拡張型心筋症治療の競争状況、市場シェア
・世界の拡張型心筋症治療市場:種類別市場規模 2015年-2020年(薬物、植込み型除細動器)
・世界の拡張型心筋症治療市場:種類別市場規模予測 2021年-2026年(薬物、植込み型除細動器)
・世界の拡張型心筋症治療市場:用途別市場規模 2015年-2020年(病院・クリニック、その他)
・世界の拡張型心筋症治療市場:用途別市場規模予測 2021年-2026年(病院・クリニック、その他)
・北米の拡張型心筋症治療市場分析:米国、カナダ
・ヨーロッパの拡張型心筋症治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの拡張型心筋症治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の拡張型心筋症治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの拡張型心筋症治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):GlaxoSmithKline、Pfizer、Novartis、Merck、Janssen Pharmaceuticals、AstraZeneca、Array BioPharma、Vericel、Celladon、Teva Pharmaceutical Industries
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Dilated Cardiomyopathy (DCM) is a condition in which heart’s left ventricle, is enlarged and weakened and the ability to pump blood is decreased.
The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R&D activities and increased awareness for timely diagnosis.

Market Analysis and Insights: Global Dilated Cardiomyopathy Treatment Market
The global Dilated Cardiomyopathy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Dilated Cardiomyopathy Treatment Scope and Market Size
Dilated Cardiomyopathy Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dilated Cardiomyopathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
GlaxoSmithKline
Pfizer
Novartis
Merck
Janssen Pharmaceuticals
AstraZeneca
Array BioPharma
Vericel
Celladon
Teva Pharmaceutical Industries

Market segment by Type, the product can be split into
Drugs
Implantable Devices
Market segment by Application, split into
Hospitals and Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Dilated Cardiomyopathy Treatment Revenue
1.4 Market by Type
1.4.1 Global Dilated Cardiomyopathy Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drugs
1.4.3 Implantable Devices
1.5 Market by Application
1.5.1 Global Dilated Cardiomyopathy Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Dilated Cardiomyopathy Treatment Market Perspective (2015-2026)
2.2 Global Dilated Cardiomyopathy Treatment Growth Trends by Regions
2.2.1 Dilated Cardiomyopathy Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Dilated Cardiomyopathy Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Dilated Cardiomyopathy Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Dilated Cardiomyopathy Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Dilated Cardiomyopathy Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Dilated Cardiomyopathy Treatment Players by Market Size
3.1.1 Global Top Dilated Cardiomyopathy Treatment Players by Revenue (2015-2020)
3.1.2 Global Dilated Cardiomyopathy Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Dilated Cardiomyopathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Dilated Cardiomyopathy Treatment Market Concentration Ratio
3.2.1 Global Dilated Cardiomyopathy Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Dilated Cardiomyopathy Treatment Revenue in 2019
3.3 Dilated Cardiomyopathy Treatment Key Players Head office and Area Served
3.4 Key Players Dilated Cardiomyopathy Treatment Product Solution and Service
3.5 Date of Enter into Dilated Cardiomyopathy Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Dilated Cardiomyopathy Treatment Historic Market Size by Type (2015-2020)
4.2 Global Dilated Cardiomyopathy Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
5.2 Global Dilated Cardiomyopathy Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Dilated Cardiomyopathy Treatment Market Size (2015-2020)
6.2 Dilated Cardiomyopathy Treatment Key Players in North America (2019-2020)
6.3 North America Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
6.4 North America Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Dilated Cardiomyopathy Treatment Market Size (2015-2020)
7.2 Dilated Cardiomyopathy Treatment Key Players in Europe (2019-2020)
7.3 Europe Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
7.4 Europe Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

8 China
8.1 China Dilated Cardiomyopathy Treatment Market Size (2015-2020)
8.2 Dilated Cardiomyopathy Treatment Key Players in China (2019-2020)
8.3 China Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
8.4 China Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Dilated Cardiomyopathy Treatment Market Size (2015-2020)
9.2 Dilated Cardiomyopathy Treatment Key Players in Japan (2019-2020)
9.3 Japan Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
9.4 Japan Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Dilated Cardiomyopathy Treatment Market Size (2015-2020)
10.2 Dilated Cardiomyopathy Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

11 India
11.1 India Dilated Cardiomyopathy Treatment Market Size (2015-2020)
11.2 Dilated Cardiomyopathy Treatment Key Players in India (2019-2020)
11.3 India Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
11.4 India Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Dilated Cardiomyopathy Treatment Market Size (2015-2020)
12.2 Dilated Cardiomyopathy Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
12.4 Central & South America Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Details
13.1.2 GlaxoSmithKline Business Overview
13.1.3 GlaxoSmithKline Dilated Cardiomyopathy Treatment Introduction
13.1.4 GlaxoSmithKline Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020))
13.1.5 GlaxoSmithKline Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer Dilated Cardiomyopathy Treatment Introduction
13.2.4 Pfizer Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Dilated Cardiomyopathy Treatment Introduction
13.3.4 Novartis Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Dilated Cardiomyopathy Treatment Introduction
13.4.4 Merck Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Janssen Pharmaceuticals
13.5.1 Janssen Pharmaceuticals Company Details
13.5.2 Janssen Pharmaceuticals Business Overview
13.5.3 Janssen Pharmaceuticals Dilated Cardiomyopathy Treatment Introduction
13.5.4 Janssen Pharmaceuticals Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.5.5 Janssen Pharmaceuticals Recent Development
13.6 AstraZeneca
13.6.1 AstraZeneca Company Details
13.6.2 AstraZeneca Business Overview
13.6.3 AstraZeneca Dilated Cardiomyopathy Treatment Introduction
13.6.4 AstraZeneca Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.6.5 AstraZeneca Recent Development
13.7 Array BioPharma
13.7.1 Array BioPharma Company Details
13.7.2 Array BioPharma Business Overview
13.7.3 Array BioPharma Dilated Cardiomyopathy Treatment Introduction
13.7.4 Array BioPharma Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.7.5 Array BioPharma Recent Development
13.8 Vericel
13.8.1 Vericel Company Details
13.8.2 Vericel Business Overview
13.8.3 Vericel Dilated Cardiomyopathy Treatment Introduction
13.8.4 Vericel Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.8.5 Vericel Recent Development
13.9 Celladon
13.9.1 Celladon Company Details
13.9.2 Celladon Business Overview
13.9.3 Celladon Dilated Cardiomyopathy Treatment Introduction
13.9.4 Celladon Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.9.5 Celladon Recent Development
13.10 Teva Pharmaceutical Industries
13.10.1 Teva Pharmaceutical Industries Company Details
13.10.2 Teva Pharmaceutical Industries Business Overview
13.10.3 Teva Pharmaceutical Industries Dilated Cardiomyopathy Treatment Introduction
13.10.4 Teva Pharmaceutical Industries Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.10.5 Teva Pharmaceutical Industries Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

GlaxoSmithKline、Pfizer、Novartis、Merck、Janssen Pharmaceuticals、AstraZeneca、Array BioPharma、Vericel、Celladon、Teva Pharmaceutical Industries

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の拡張型心筋症治療市場2026:インサイト・予測(Global Dilated Cardiomyopathy Treatment Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。